Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01927341
Title Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | CAN | BEL

Facility Status City State Zip Country Details
University of California at Los Angeles Dept of Onc Los Angeles California 90095 United States Details
Memorial Sloan Kettering Cancer Center Oncology Dept New York New York 90033 United States Details
Pfizer Investigative Site Leuven 3000 Belgium Details
Pfizer Investigative Site Toronto Ontario M5G 2M9 Canada Details
Pfizer Investigative Site Toulouse Cedex 9 31059 France Details
Pfizer Investigative Site Milano MI 20162 Italy Details
Pfizer Investigative Site Amsterdam 1066 CX Netherlands Details
Pfizer Investigative Site Barcelona Catalunya 08035 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field